A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study is an open label, multicenter study with two phases:
- A dose escalation phase of Romidepsin administered IV at day 1 and 8 or at day 1 without
day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone
(CHOP)administered every 3 weeks for 8 cycles in patients with T-cell lymphoma.
- An expansion phase in order to assess the safety and the efficacy of the association of
the recommended dose of Romidepsin associated with CHOP in a population of patients with
T-cell lymphoma.